Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
<p>Abstract</p> <p>Introduction</p> <p>Natalizumab is a new treatment for relapsing-remitting multiple sclerosis. Because of limited experience of this treatment, medical professionals must be alert to possible side effects.</p> <p>Case presentation</p>...
Main Authors: | Gatzonis Stylianos, Siatouni Anna |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2009-08-01
|
Series: | Journal of Medical Case Reports |
Online Access: | http://www.jmedicalcasereports.com/content/3/1/8955 |
Similar Items
-
Natalizumab for relapsing-remitting multiple sclerosis
by: A. Horga, et al.
Published: (2011-01-01) -
Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
by: Mehdi Rezaee, et al.
Published: (2022-01-01) -
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
by: Diego Cadavid, et al.
Published: (2013-01-01) -
Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life
by: Planas R, et al.
Published: (2014-04-01) -
Effect of Rituximab Compared with Natalizumab and Fingolimod in Patients with Relapsing–Remitting Multiple Sclerosis: A Cohort Study
by: Martha Rocio Hernández-Preciado, et al.
Published: (2022-06-01)